[Safety and effectiveness of salvage therapy in HIV patients]. 2012

M C Serrano Vicente, and H Navarro Aznárez, and P Carrera Lasfuentes, and M R Abad Sazatornil, and O Horna Oreja, and M J Rabanaque Hernández
Servicio de Farmacia, Hospital Universitario Miguel Servet, Zaragoza, España. marisevi@gmail.com

BACKGROUND The treatment used after failure of at least two lines of antiretroviral treatment in HIV patients is called salvage therapy. The study aims to describe the characteristics of HIV patients subjected to such a regimen, and determine the safety and effectiveness of treatment with tipranavir (TPV), darunavir (DRV), enfuvirtide (ENF) and etravirine (ETR) combined with an optimised antiretroviral regimen. METHODS HIV patients treated with ENF, TPV, DRV or ETR in a tertiary hospital infectious diseases department subjected to at least 12 weeks treatment. The patient characteristics are described and the effectiveness, durability and adherence to the treatment analysed. RESULTS There were 28 patients studied, with an average of 10 treatment regimens prior to starting salvage therapy (SD=3.5; 95% CI, 8.9-11.1). A total of 85.7% patients had treatment adherence >90%. For ENF, 70.8% of the treatment lines were suspended during follow-up. After salvage therapy, the percentage of patients with viral load (VL) <400 copies/ml doubled, and cases with undetectable CV (<50 copies/ml) almost tripled. The treatments used did not change the liver or kidney profiles; however, they changed the lipid profile and increased the percentage of patients with hyperglycaemia. CONCLUSIONS The salvage therapy studied was effective. Good adherence to the therapy is critical for its effectiveness.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010349 Patient Compliance Voluntary cooperation of the patient in following a prescribed regimen. Client Adherence,Client Compliance,Non-Adherent Patient,Patient Adherence,Patient Cooperation,Patient Noncompliance,Patient Non-Adherence,Patient Non-Compliance,Patient Nonadherence,Therapeutic Compliance,Treatment Compliance,Adherence, Client,Adherence, Patient,Client Compliances,Compliance, Client,Compliance, Patient,Compliance, Therapeutic,Compliance, Treatment,Cooperation, Patient,Non Adherent Patient,Non-Adherence, Patient,Non-Adherent Patients,Non-Compliance, Patient,Nonadherence, Patient,Noncompliance, Patient,Patient Non Adherence,Patient Non Compliance,Patient, Non-Adherent,Therapeutic Compliances,Treatment Compliances
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D016019 Survival Analysis A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function. Analysis, Survival,Analyses, Survival,Survival Analyses
D016879 Salvage Therapy A therapeutic approach, involving chemotherapy, radiation therapy, or surgery, after initial regimens have failed to lead to improvement in a patient's condition. Salvage therapy is most often used for neoplastic diseases. Salvage Treatment,Therapy, Salvage,Salvage Therapies,Salvage Treatments,Therapies, Salvage,Treatment, Salvage,Treatments, Salvage
D017211 Treatment Failure A measure of the quality of health care by assessment of unsuccessful results of management and procedures used in combating disease, in individual cases or series. Failure, Treatment,Failures, Treatment,Treatment Failures

Related Publications

M C Serrano Vicente, and H Navarro Aznárez, and P Carrera Lasfuentes, and M R Abad Sazatornil, and O Horna Oreja, and M J Rabanaque Hernández
January 2005, Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria,
M C Serrano Vicente, and H Navarro Aznárez, and P Carrera Lasfuentes, and M R Abad Sazatornil, and O Horna Oreja, and M J Rabanaque Hernández
September 2016, Journal of infection in developing countries,
M C Serrano Vicente, and H Navarro Aznárez, and P Carrera Lasfuentes, and M R Abad Sazatornil, and O Horna Oreja, and M J Rabanaque Hernández
February 1993, Transfusion,
M C Serrano Vicente, and H Navarro Aznárez, and P Carrera Lasfuentes, and M R Abad Sazatornil, and O Horna Oreja, and M J Rabanaque Hernández
April 2011, Journal of acquired immune deficiency syndromes (1999),
M C Serrano Vicente, and H Navarro Aznárez, and P Carrera Lasfuentes, and M R Abad Sazatornil, and O Horna Oreja, and M J Rabanaque Hernández
April 2004, MMW Fortschritte der Medizin,
M C Serrano Vicente, and H Navarro Aznárez, and P Carrera Lasfuentes, and M R Abad Sazatornil, and O Horna Oreja, and M J Rabanaque Hernández
April 2002, Nihon rinsho. Japanese journal of clinical medicine,
M C Serrano Vicente, and H Navarro Aznárez, and P Carrera Lasfuentes, and M R Abad Sazatornil, and O Horna Oreja, and M J Rabanaque Hernández
February 2002, Expert opinion on pharmacotherapy,
M C Serrano Vicente, and H Navarro Aznárez, and P Carrera Lasfuentes, and M R Abad Sazatornil, and O Horna Oreja, and M J Rabanaque Hernández
April 2005, MMW Fortschritte der Medizin,
M C Serrano Vicente, and H Navarro Aznárez, and P Carrera Lasfuentes, and M R Abad Sazatornil, and O Horna Oreja, and M J Rabanaque Hernández
May 2008, Current opinion in HIV and AIDS,
M C Serrano Vicente, and H Navarro Aznárez, and P Carrera Lasfuentes, and M R Abad Sazatornil, and O Horna Oreja, and M J Rabanaque Hernández
February 2012, Alcoholism, clinical and experimental research,
Copied contents to your clipboard!